Literature DB >> 9625267

A pharmacokinetic evaluation of pravastatin in middle-aged and elderly volunteers.

S Sigurbjörnsson1, T Kjartansdóttir, M Jóhannsson, J Kristinsson, G Sigurdsson.   

Abstract

The pharmacokinetics of pravastatin, a serum-cholesterol-lowering drug, were studied in 20 middle-aged (46-59 years old, n = 8) and elderly subjects (60-81 years old, n = 12). Pravastatin serum levels were determined by HPLC and solid phase extraction. Cmax was 48.9 +/- 7.1 ng/ml (mean +/- SEM, n = 20), and the mean AUC0-4.5h was 104.4 ng x h/ml (n = 5) for a 20 mg daily oral dose. A great interindividual variability was found for Cmax, which varied from 6.2 ng/ml to 117.8 ng/ml on the 20 mg dose. As could be expected, Cmax and AUC0-4.5h were dose-related, but Tmax and t1/2 were not. In six cases, the elimination of the drug in serum could be described by a single phase but in four cases with two phases. No significant difference was found in Cmax between the middle-aged and the elderly or between males and females.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9625267     DOI: 10.1007/BF03189821

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  12 in total

1.  ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterogenesis produced by Penicillium citrinium.

Authors:  A Endo; M Kuroda; Y Tsujita
Journal:  J Antibiot (Tokyo)       Date:  1976-12       Impact factor: 2.649

2.  Pravastatin therapy in primary moderate hypercholesterolaemia: changes in metabolism of apolipoprotein B-containing lipoproteins.

Authors:  G L Vega; R M Krauss; S M Grundy
Journal:  J Intern Med       Date:  1990-02       Impact factor: 8.989

3.  Determination of pravastatin sodium and its major metabolites in human serum/plasma by capillary gas chromatography/negative ion chemical ionization mass spectrometry.

Authors:  P T Funke; E Ivashkiv; M E Arnold; A I Cohen
Journal:  Biomed Environ Mass Spectrom       Date:  1989-10

4.  Pharmacokinetics and pharmacodynamics of pravastatin alone and with cholestyramine in hypercholesterolemia.

Authors:  H Y Pan; A R DeVault; B J Swites; D Whigan; E Ivashkiv; D A Willard; D Brescia
Journal:  Clin Pharmacol Ther       Date:  1990-08       Impact factor: 6.875

5.  Effects of lovastatin in diabetic patients treated with chlorpropamide.

Authors:  B F Johnson; P LaBelle; J Wilson; J Allan; R V Zupkis; P D Ronca
Journal:  Clin Pharmacol Ther       Date:  1990-10       Impact factor: 6.875

6.  Determination of the HMG-CoA reductase inhibitors simvastatin, lovastatin, and pravastatin in plasma by gas chromatography/chemical ionization mass spectrometry.

Authors:  M J Morris; J D Gilbert; J Y Hsieh; B K Matuszewski; H G Ramjit; W F Bayne
Journal:  Biol Mass Spectrom       Date:  1993-01

7.  Plasma lipoprotein changes after treatment with pravastatin and gemfibrozil in patients with familial hypercholesterolemia.

Authors:  G Franceschini; M Sirtori; V Vaccarino; G Gianfranceschi; G Chiesa; C R Sirtori
Journal:  J Lab Clin Med       Date:  1989-09

Review 8.  Discovery, biochemistry and biology of lovastatin.

Authors:  A W Alberts
Journal:  Am J Cardiol       Date:  1988-11-11       Impact factor: 2.778

9.  Pharmacokinetics of pravastatin in elderly versus young men and women.

Authors:  H Y Pan; A P Waclawski; P T Funke; D Whigan
Journal:  Ann Pharmacother       Date:  1993-09       Impact factor: 3.154

10.  Dose-dependent hypolipidemic effect of an inhibitor of HMG-CoA reductase, pravastatin (CS-514), in hypercholesterolemic subjects. A double blind test.

Authors:  Y Saito; Y Goto; N Nakaya; Y Hata; Y Homma; C Naito; H Hayashi; H Ito; M Yamamoto; I Takeuchi
Journal:  Atherosclerosis       Date:  1988-08       Impact factor: 5.162

View more
  2 in total

Review 1.  Clinical pharmacokinetics of pravastatin: mechanisms of pharmacokinetic events.

Authors:  T Hatanaka
Journal:  Clin Pharmacokinet       Date:  2000-12       Impact factor: 6.447

2.  Quantitative determination of pravastatin and its metabolite 3α-hydroxy pravastatin in plasma and urine of pregnant patients by LC-MS/MS.

Authors:  Xing Zhang; Daria I Vernikovskaya; Xiaoming Wang; Tatiana N Nanovskaya; Maged Costantine; Gary D V Hankins; Mahmoud S Ahmed
Journal:  Biomed Chromatogr       Date:  2015-09-11       Impact factor: 1.902

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.